Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) and classical Hodgkin lymphoma (CHL) are classified separately because of their distinct clinical and pathologic features. Whereas Epstein-Barr virus (EBV) is detected in the neoplastic cells of 25% to 70% of CHL, NLPHL is generally considered to be EBV À . We assessed EBV status in 302 pediatric and adult cases of NLPHL. A total of 145 pediatric (age 18 y or younger) and 157 adult cases of NLPHL were retrieved from 3 North American centers and tested for EBV by in situ hybridization (EBV-encoded small RNA). Clinical and pathologic features were analyzed. Five (3.4%) pediatric and 7 (4.5%) adult NLPHL cases contained EBV + lymphocyte-predominant (LP) cells. Although all 12 cases met the criteria for diagnosis of NLPHL, atypical features were present, including capsular fibrosis, atrophic germinal centers, and pleomorphic or atypical LP cells. CD20 and OCT-2 were strongly and diffusely positive in all except 1 case. However, PAX5 and CD79a were weak and/or variable in 7/8 and 6/6 cases tested, respectively. EBV + cases were more likely to be CD30 + (75%) compared with EBV À cases (25%) (P = 0.0007); CD15 was negative in all cases. Our results show that EBV + LP cells may occur in NLPHL. Distinguishing EBV + NLPHL from CHL can be challenging, as EBV + NLPHL can have partial expression of CD30 and weak PAX5 staining as well as pleomorphic-appearing LP cells. However, the overall appearance and maintenance of B-cell phenotype, with strong and diffuse CD20 and OCT-2 expression, support the diagnosis of NLPHL in these cases.
N odular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an infrequently encountered B-cell neoplasm most commonly involving the cervical, axillary, or inguinal lymph nodes of young adult men. The neoplastic cells comprise a minor component of the lymphoid tissue on histologic sections and are termed lymphocytepredominant (LP) cells. LP cells, previously known as lymphocytic and histiocytic cells, are large with scant cytoplasm, a single multilobated or folded nucleus, and multiple small basophilic nucleoli. The cellular milieu consists of small lymphocytes and histiocytes with underlying expanded meshworks of follicular dendritic cells. Small B cells are typically numerous in early lesions but can decrease over time with replacement of the follicular structure. 1 LP cells maintain a B-cell phenotype, with expression of CD20, CD79a, OCT-2, and BOB.1 as well as CD45 and BCL6. LP cells may also be positive for EMA, but CD30 and CD15 are typically negative. [2] [3] [4] The prognosis of NLPHL patients is generally good, although the disease frequently relapses after prolonged periods of remission. 5 NLPHL and classical Hodgkin lymphoma (CHL) share some similarities but overall have disparate epidemiologic, clinical, pathologic, and prognostic features, justifying their separation into discrete entities. One helpful feature is the frequent detection of Epstein-Barr virus (EBV) in the neoplastic Hodgkin and Reed-Sternberg (HRS) cells of CHL, whereas EBV is reported to be absent in most cases of NLPHL. 4 Although cases of EBV + NLPHL have been reported in the literature, mainly originating from Asia and Latin America, [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] no large-scale study has been performed to determine the occurrence of EBV + NLPHL in a North American patient population. Thus, we aimed to investigate the frequency of EBV infection in LP cells of NLPHL cases submitted to 3 large reference centers in the United States and Canada.
MATERIALS AND METHODS
Following approval by the institutional review board at each location, the archives of the National Cancer Institute (NCI), the Massachusetts General Hospital (MGH) and the British Columbia Cancer Agency (BCCA) were searched for cases diagnosed as NLPHL in which EBV-encoded small RNA in situ hybridization (EBER ISH) had been performed or for which material was available to perform this test. Available clinical data, histologic features, and immunohistochemical (IHC) results were recorded for each case. IHC stains and EBER had been performed by standard methods at each institution and included stains for CD20, OCT-2, CD30, CD15, and CD3 in most cases. All EBV + cases underwent central review at the NCI by a panel of 4 pathologists (A.R.H., A.N., S.P., and E.S.J.). Two cases initially identified as possible EBV + NLPHL were later excluded after central review because they were felt to be aggressive B-cell lymphomas. A total of 302 NLPHL cases (220 NCI, 51 MGH, 31 BCCA) diagnosed between the years 2000 and 2013 were included in the study; 30 of these cases have been previously published by 1 of the institutions. 21 All EBV + cases with available unstained slides or paraffin-embedded blocks were subjected to an expanded IHC panel including CD20, PAX5, CD79a, OCT-2, BOB.1, CD30, CD15, BCL6, EMA, IgD, CD3, PD1, CD57, CD21, and LMP1. Double staining for CD20/EBER and PD1/EBER was performed on 1 case. For double staining EBER was performed first, followed by CD20 and PD1, respectively, according to the standard procedure of single staining. The EBV + cases were further categorized according to the architectural and immunohistologic features described by Fan et al. 1 The patterns were assigned by consensus of the panel of 4 pathologists on the basis of review of all available histologic and IHC slides. Patterns were included if they comprised at least 5% of the total lymphoma surface area in the available slides.
Patient clinical characteristics were summarized as numbers and percentages for categorical variables and median and range for continuous variables. Comparisons between categorical variables were analyzed by the Fisher exact test, and the Mann-Whitney U test was used for numerical comparisons between groups. Statistical analyses were calculated using the Prism software package, version 5 (GraphPad Software Inc., La Jolla, CA). P values of r0.05 were regarded as statistically significant.
RESULTS

Assessment of 302 NLPHL Cases
The study included 145 pediatric (age 18 y or younger) and 157 adult (age above 18 y) patients ( Table 1) . NLPHL affected predominantly male individuals, with a significantly higher male:female ratio in children (11:1) than in adults (3.5:1) (P = 0.0005). The median age was 12 years in pediatric patients and 35 years in adults. Biopsied lymph nodes in children were more commonly cervical (P < 0.0001) and less commonly axillary (P < 0.0001) or intra-abdominal (P = 0.001) than in adults (data not shown).
LP cells maintained a B-cell phenotype, with positive staining for CD20 in 99% of all cases, CD79a in 98%, PAX5 in 100%, OCT-2 in 99%, and BOB.1 in 90%. In addition, LP cells expressed BCL6 in 97% and EMA in 42% of cases. LP cells were CD30 + in 75/270 (28%) cases, but the staining was usually focal or heterogenous in LP cells. Eight cases expressed CD15 in LP cells (8/266, 3%), all of which were EBV À , and no cases coexpressed CD30 and CD15. No differences were identified in the immunoprofile of LP cells between pediatric and adult age groups (data not shown), with the exception of IgD: 87/124 (70%) of pediatric cases versus 32/84 (38%) of adult (>18 y) cases tested expressed IgD in LP cells (P < 0.0001). Most of these patients were male, with a male:female ratio of 16:1. The median age of the IgD + cases was 14 years, compared with 21 years for the IgD À cases (P < 0.0001); however, all patients with IgD + LP cells were 25 years or younger. The median age of all cases tested for IgD was 16, whereas the median age of those cases not tested for IgD was 37, indicating some selection bias in the performance of this test.
Occasional background small lymphocytes and/or immunoblasts were EBV + by EBER ISH in 21 (14%) pediatric and 23 (15%) adult cases. In addition, EBER ISH was positive in the LP cells of 5 (3.4%) pediatric and 7 (4.5%) adult patients, and these 12 cases were the main focus of our study.
Description of 12 Cases of EBV + NLPHL
The patients' ages ranged from 4 to 62 years (median 44 y) ( Table 2 ). All 5 pediatric patients and 5/7 (71%) adult patients were male. One pediatric patient was native to Saudi Arabia, a second was from Paraguay, and a third was of American Samoan ancestry but currently residing in Hawaii. The remaining patients were residents of the United States or Canada. Biopsied lymph nodes included cervical (4), axillary (4), submandibular (2), and supraclavicular (2) locations. Patient 12 had a history of stage IA CHL diagnosed 9 years earlier, but this material was not available for our review. Only limited information regarding EBV viral loads, serologic studies, and follow-up data was available for these 12 patients. Of the 6 patients with known clinical staging, 2 were Ann Arbor stage IA, 1 was stage II, 2 were stage III, and 1 was stage IV. Two patients were treated with combined chemotherapy and radiotherapy, and 2 patients were treated with therapy of unknown type; the treatment status of the remaining 8 patients is unknown. Of the 6 patients with available follow-up information, 4 are free of disease 1.3, 2, 3.5, and 7.5 years after diagnosis; 1 patient relapsed 6 years after diagnosis, and 1 patient has reduced lymphadenopathy with therapy currently ongoing.
On review by the panel, all 12 EBV + cases met the diagnostic criteria for NLPHL based on the histologic pattern and IHC expression profile. All cases displayed at least a partially nodular architectural pattern ( Fig. 1A) ; cases from 3 children (cases 1 to 3) and 1 adult (case 12) also exhibited diffuse areas. However, none of the EBV + cases showed progression to T-cell/histiocyte-rich large B-cell lymphoma-like areas in the material submitted for review. The nodular areas contained small lymphocytes, histiocytes, and large atypical cells consistent with LP cells (Figs. 1B, 2A). Epithelioid histiocytes were identified in 11/12 patients, including necrotizing granulomas in 1 case (case 6) ( Fig. 3B ). One case (case 2) exhibited geographic areas of necrosis. Residual germinal centers were seen in 8 cases, and 3 of these demonstrated partially involuted germinal centers within the nodules. Focal capsular sclerosis was identified in 5/12 (42%) cases, and 3 of these also contained focal bands of nodular fibrosis (Fig. 3A) . The LP cells were not only seen within nodules but were also present between the nodules in 3 adult patients and in the 4 above noted cases with diffuse areas. All of the pediatric cases with diffuse areas contained many mummified and/or apoptotic cells, a feature also noted in 3 purely nodular adult cases (cases 8, 9 and 10). Tumor cells displayed marked pleomorphism in 2 cases (cases 8 and 10). The immunophenotypes of the EBV + and EBV À NLPHL cases are summarized in Table 2 . Three EBER + cases were uniformly LMP1 + , 2 cases were focally LMP1 + , and 1 case was LMP1 À . The LP cells expressed CD20 (12/12) ( Fig. 1C inset, Fig. 3E ), PAX5 (8/8), CD79a (6/6), and OCT-2 (11/11) ( Fig. 1E ) in all cases tested and BOB.1 (3/5, 60%) in the majority of tested cases. CD20 expression was strong and diffuse in 11/12 (92%) cases, and OCT-2 was strongly and diffusely positive in all 11 cases tested. Confirmation that the EBV + cells were also strongly positive for CD20 was demonstrated on case 12 with double staining (Fig. 2B ). PAX5 ( Fig. 2C ) and CD79a (Fig. 3F ) were weak and/or variable in 7/8 (88%) and in all 6/6 (100%) cases tested, respectively. BCL6 was positive in LP cell nuclei in 10/11 cases (91%) ( Fig. 2D ), although the staining was focal and/or weak in 7 cases. Two pediatric but no adult cases were positive for IgD ( Fig. 2E) . It is noteworthy that CD30 was at least focally or weakly positive in 75% (9/12) of EBV + NLPHLs (Fig. 3G) , in contrast to 26% (66/258) EBV À NLPHLs (P = 0.0007). None of the EBV + cases demonstrated strong, uniform CD30 staining, and all were negative for CD15. No EMA expression was seen in the 8 EBV + cases tested, versus an absence in FIGURE 1. Case 6 had the typical morphology and immunophenotype for NLPHL but was positive for EBV. A, The normal lymph node architecture was effaced by a nodular infiltrate consisting of small lymphocytes, epithelioid histiocytes, and scattered LP cells (B) with multilobated nuclei. The small lymphocytes express CD20 (C) and IgD (D). The LP cells are strongly positive for CD20 (C inset) and OCT-2 (E), are rosetted by CD3 + (F) and PD1 + (G) T cells, and are EBV + by EBER (H).
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EBV Expressed in LP Cells of NLPHL 59/134 (44%) EBV À NLPHL cases (P = 0.02). In the background cellularity, the nodular areas were composed mostly of CD20 + and IgD + small B cells (Figs. 1C, D) . CD21 + follicular dendritic cell meshworks were identified in all 11 cases stained, with a notable expansion of the meshworks in 8 cases. CD3 + T-cell rosettes surrounding the LP cells were observed in 11/12 cases (92%) (Fig. 1F ). Three of 4 tested cases contained increased CD57 + cells, including 2 with rosettes around LP cells. Increased PD1 + cells were present in 8/10 cases (80%), and these PD1 + cells formed rosettes around LP cells in 9/10 cases (90%) (Fig. 1G ). Double staining with PD1 and EBER confirmed rosetting of EBER + LP cells by the PD1 + cells (Fig. 2F) . Fig. 1 ) exhibiting a prominent granulomatous reaction with focal areas of necrosis. C, In case 10 the low-power nodular appearance is typical. D, The LP cells, however, are larger than expected with more pleomorphic and polylobated nuclei arranged in clusters. They are strongly positive for CD20 (E), which also highlights the small B cells in the background. They are weakly positive for CD79a (F) and CD30 (G). H, EBER was positive.
DISCUSSION
EBV, a linear 172 kbp double-stranded DNA herpesvirus, preferentially infects human B cells through the CD21 surface antigen and establishes lifelong persistent infection in >90% of the world's population. 22 Evidence of EBV infection can be found in the neoplastic cells of several hematopoietic and nonhematopoietic malignancies. In particular, EBV is frequently identified in the neoplastic cells of CHL (predominantly of mixed cellularity type), in some T-cell lymphomas, in diffuse large Bcell lymphomas (affecting elderly or immunocompromised patients), and in Burkitt lymphoma. However, the malignant cells of NLPHL are, in general, considered to be negative for EBV, 4 and, indeed, none of the 3 centers involved in this study routinely performs testing for EBV in NLPHL. Nevertheless, all 3 institutions have received EBV + NLPHL cases in consultation, and thus we sought to identify whether EBV positivity in NLPHL may be underrecognized. We found EBV in slightly <4% of the 302 cases analyzed. As we included EBV + cases sent in consultation, the incidence in unselected NLPHL cases may be even lower.
On the basis of a comprehensive literature review we identified 39 cases of NLPHL reported to be positive for EBV in prior studies [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] (Table 3 ). Most positive cases were identified in reports from South America, Asia, or Africa, where there is a greater prevalence of EBV-related lymphoproliferative disorders and a higher prevalence of EBV in CHL as well. Only 1 positive case from the United States has been reported, which was encountered in a study of 16 pediatric cases. 17 Another confounding factor in assessing the EBV status of NLPHL is that before the year 2000, cases diagnosed as NLPHL likely also included cases of lymphocyte-rich CHL (LRCHL), 4 as these 2 forms of Hodgkin lymphoma were not distinguished in older series. Only 2 reports identifying EBV in NLPHL have been published since 2000. 7, 18 In CHL, EBV positivity is associated with the host's geographic origin and immune status and is more common in developing countries. For example, upward of 80% of CHL cases in Africa, 70% to 80% of cases in Latin America, and about 65% of reported cases in Asian populations are EBV + , whereas <40% of all cases in the United States and Europe are EBV + . 16, 17, 23, 24 Two of the 12 patients in our study were native to the Middle East (Saudi Arabia) and South America (Paraguay), with a third patient originating from American Samoa but living in the United States. The ethnicity of all 302 of our cases is not known for certain, but most were residents of the United States or Canada at the time of biopsy. The geographic differences observed in CHL are thought to reflect genetic variation, socioeconomic status, age, and immune status. Complete histories with medical and social information to include socioeconomic status and immune function were not available for most patients in our study and thus could not be comprehensively assessed. Although the 2 non-Western cases account for 17% of our EBV + NLPHL cases, their exclusion would result in only a slightly lower overall rate in the studied population. No age predilection was identified in the EBV + patients, with a similar occurrence in both children (3.4%) and adults (4.5%). In contrast, EBV + CHL is reported to be more frequent in pediatric patients (children less than 10 y of age). 25 Both the methods and interpretation of testing are critical considerations when evaluating EBV status in hematopoietic neoplasms. Previous reports describing EBV in NLPHL have mostly utilized IHC (LMP1 expression) and/or ISH (EBER); some studies confirmed results by polymerase chain reaction (PCR). However, PCR performed on tissue may produce confounding results if lymphocytes other than LP cells contain EBV. Indeed, we found scattered EBV + non-LP cells in 15% of our NLPHL cases, with similar incidences in both children and adults. This finding has also been reported in the literature for both NLPHL 26 and for CHL. 9, 24, 27 The presence of EBV in non-neoplastic cells indicates prior EBV infection but may produce false-positive results when assessed only by PCR methods. Thus, visual examination to identify the cells that actually contain EBV is required to confirm that the virus is present within the neoplastic cells. EBV, when detected in CHL, has been shown to be clonal, indicating infection of the neoplastic clone early in disease evolution. 28 Clonality testing for EBV requires isolation of DNA from fresh or frozen tissue samples, and this material was not available in our study cohort. Therefore, we could not assess at what point the LP cells acquired the EBV infection. The diagnosis of NLPHL in some older series is difficult to confirm, as LRCHL was first proposed as distinct from NLPHL in 1994 29 and was not reliably segregated in clinical series until some years later. 30 Although these 2 entities are usually distinct and can be reliably distinguished on the basis of morphology and IHC, a few of our cases did demonstrate overlapping features. For example, regressed germinal centers, often visualized at the periphery of the nodules in LRCHL, were identified in 3 of the 12 EBV + NLPHL cases. LP cells with a Reed-Sternberg cell-like appearance were seen in a subset of the cases. Not only are morphologic features of NLPHL and LRCHL sometimes similar, but their immunophenotypes may also overlap. CD15 expression has been reported in some cases of NLPHL 3, 18 and was identified in a few EBV À cases (8/302, 2.7%) in our study, but not in any that were EBV + . A significant percentage (29%) of our NLPHL cases showed some staining of LP cells for CD30, although they did not typically have the diffuse and strong expression seen in the HRS cells of CHL. In contrast, none of the NLPHL cases tested by Nam-Cha et al 18 was reported to be positive for CD30. Although this disparity may be due to differences in antibody choice or staining techniques, CD30 + cases were identified from all 3 participating institutions in our study. Moreover, a recent study found a relatively high incidence of variable CD30 expression in LP cells. 2 Infection with EBV can alter the B-cell immunophenotype, an observation that may help explain the staining patterns in some of our EBV + cases. For example, PAX5 and CD79a were weakly and variably expressed, respectively, in 88% and 100% of the EBV + NLPHL cases in our series. LMP2A has been shown to interfere with the expression of transcription factors, including PAX5, during the development of B cells. 31 LMP1 changes the gene expression profile of germinal center B cells to resemble CHL cell lines, induces the expression of ID2 (a negative regulator of B-cell differentiation), and downregulates expression of B-cell receptor components, including CD79a. 32 EBNA2 downregulates BCL6 expression in non-Hodgkin lymphoma cell lines. 33 Furthermore, a study of diffuse large B-cell lymphoma in human immunodeficiency viruspositive patients found increased CD30 expression and reduced BCL6 expression in EBV + as compared with EBV À cases. 34 The EBV + NLPHL cases in our series were significantly more likely to be CD30 + and weakly express BCL6 than the EBV À cases.
As the differential diagnosis of CHL versus NLPHL may be raised by EBV + cases, particularly when atypical morphologic and/or immunophenotypic features are present, how does one render a final diagnosis of EBV + NLPHL? This distinction is clinically relevant, as NLPHL and CHL have different prognoses and clinical behavior and may have differing treatments. 35 An IHC pattern indicating overall maintenance of B-cell phenotype is one helpful feature. LP cells are readily identified using OCT-2, which is strongly expressed in comparison with the background small B cells and was consistently expressed in both EBV + and EBV À cases. IgD expression in NLPHL, identified in some young patients, 21 should exclude most cases of CHL, although rare cases of LRCHL have been reported to express IgD in HRS cells. 18 Rosetting of malignant cells by PD1 + T cells is another feature universally seen in NLPHL, although noted by some authors to also occur in a subset of cases of LRCHL. 18, 36 Unexpected IHC results such as weak and/or variable PAX5 in LP cells may provide an indication that EBV could be present. If testing for EBV is desired, EBER ISH is recommended rather than LMP1 IHC, as the latter can have more variable or absent staining.
A few of the cases we report were sent to one of our institutions for a second diagnostic opinion only because they were found to be positive for EBV. Although this may have increased the number of positive cases in our series, we controlled for this factor by examining a large number of NLPHL cases from our files. Relapse and survival data comparing EBV + and EBV À groups would be of interest, but we were unable to obtain sufficient follow-up information to reliably assess outcome in our patient cohort.
In summary, EBV positivity in the LP cells of NLPHL may occasionally occur in North American patients, in both adults and children. Distinguishing these cases from LRCHL can be diagnostically challenging, as these cases can have partial expression of CD30, weak PAX5 staining, and an atypical appearance of LP cells. However, the architecture and characteristics of the background cells and overall maintenance of B-cell phenotype in the LP cells (with strong and diffuse CD20 and OCT-2 expression) support a diagnosis of NLPHL and help avoid an erroneous diagnosis of CHL.
